VIP
Typical Dosage
Intranasal 300-600 mcg
Injection: 50-100 mcg
Administration
Nasal • Injection
Half-Life
Very short in circulation, often only minutes
Mechanism of Action
Bronchodilation and vasodilation research|Immune modulation|Gut-lung axis studies|Neuropeptide signaling
Research Protocol Summary
Evidence Level
Human Clinical / Established
Typical Protocol Duration
6-9 months
Species Studied
Human • Mouse • Rat
Administration Schedule
Daily
Studies
Research Availability
Individual PubMed records have not been mapped for this entry yet. Use the linked PubMed search to review the current literature directly.
Related resources
Research Feedback
0 approved
For research discussion only. Community feedback is moderated and shown here as aggregated insights after approval.
Loading approved insights…